Recursion Pharmaceuticals Inc - Ordinary Shares - Class A
RXRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.69B
Close$
Share Statistics
| Market cap | $1.69 Billion |
|---|---|
| Enterprise Value | $1.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.44 |
| Beta | 1 |
| Outstanding Shares | 532,460,085 |
Return
| Return on Equity | -56.71% |
|---|---|
| Return on Assets | -42.79% |
| Return on Invested Capital | -51.17% |
Valuation & Multiples
| P/E Ratio | -3.1 |
|---|---|
| PEG | 13.02 |
| Price to Sales | - |
| Price to Book Ratio | 3.31 |
| Enterprise Value to Revenue | 22.48 |
| Enterprise Value to EBIT | -2.21 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$10.97 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$14.16 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7630▲ 12.15% |
|---|---|
| Total Calls | 90,298▼ 98.04% |
| Total Puts | 68,900▼ 97.66% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.52%▼ 50.61% |
|---|---|
| Total Invested | $476.23M▼ 53.86% |
| Investors Holding | 158▼ 192.00% |
ESG Score
No data
About Recursion Pharmaceuticals Inc
218 employeesRecursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patient...